Review of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity-Reference-Cited by-同舟云学术

Review of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity

Published:2017-08-23 Issue: Volume:8 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Jansen Marleen E.,Rigter T.,Rodenburg W.,Fleur T. M. C.,Houwink E. J. F.,Weda M.,Cornel Martina C.

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference34 articles.

1. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin;Brunham;Pharmacogenomics J.,2012

2. Genetic tests: clinical validity and clinical utility;Burke;Curr. Protoc. Human Genet.,2015

3. Power failure: why small sample size undermines the reliability of neuroscience;Button;Nat. Rev. Neurosci.,2013

4. The clinical pharmacogenetics implementation consortium (CPIC): Facilitating the adoption of pharmacogenetics into routine clinical practice and the electronic health record;Caudle;Pharmacotherapy,2014

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Considerations in Clinical Laboratory Development of Pharmacogenomic Testing;Advances in Molecular Pathology;2024-07

2. When the same treatment has different response: The role of pharmacogenomics in statin therapy;Biomedicine & Pharmacotherapy;2024-01

3. Predictive Value of SLCO1B1 c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users;Genes;2023-02-10

4. Polypharmacy and precision medicine;Cambridge Prisms: Precision Medicine;2023

5. Should we test for SLCO1B1 genotype before prescribing statins?—a discussion of clinical trial results;Annals of Translational Medicine;2022-12